NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $4.48 +0.10 (+2.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.38▼$4.5450-Day Range$2.92▼$4.9652-Week Range$1.11▼$6.72Volume735,203 shsAverage Volume1.53 million shsMarket Capitalization$506.62 millionP/E RatioN/ADividend YieldN/APrice Target$8.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Absci alerts: Email Address Absci MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside87.5% Upside$8.40 Price TargetShort InterestBearish13.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 3 Articles This WeekInsider TradingSelling Shares$13.74 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.80) to ($0.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.74 out of 5 starsMedical Sector688th out of 936 stocksCommercial Physical Research Industry9th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 3 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.25% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Absci has recently increased by 35.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABSI. Previous Next 2.5 News and Social Media Coverage News SentimentAbsci has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Absci this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows10 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Absci insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,738,898.00 in company stock.Percentage Held by InsidersOnly 9.81% of the stock of Absci is held by insiders.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.80) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -3.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Absci Stock (NASDAQ:ABSI)Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More ABSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSI Stock News HeadlinesJuly 10, 2024 | globenewswire.comAbsci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024July 3, 2024 | globenewswire.comAbsci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 28, 2024 | globenewswire.comAbsci to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 16, 2024 | seekingalpha.comAbsci: 'AI' Tag Keeping Company Afloat While Searching For Right FormulaMay 16, 2024 | investorplace.com7 Pharma Stocks Harnessing AI Brainpower for Big BreakthroughsMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed on AbSci’s Financial Stability and Lead Candidate ABS-101’s Market PotentialMay 15, 2024 | finance.yahoo.comAbsci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ...July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 14, 2024 | investorplace.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | globenewswire.comAbsci Reports Business Updates and First Quarter 2024 Financial and Operating ResultsApril 20, 2024 | finance.yahoo.comAbsci Corporation (ABSI)April 16, 2024 | finance.yahoo.comAbsci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024March 28, 2024 | finance.yahoo.comAbsci to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 23, 2024 | finance.yahoo.comAbsci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net LossMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbSci: Promising Pipeline and Strategic Partnerships Signal GrowthMarch 21, 2024 | benzinga.comAbsci: Q4 Earnings InsightsMarch 21, 2024 | investorplace.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023See More Headlines Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Confirmed)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CUSIPN/A CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$8.40 High Stock Price Target$13.00 Low Stock Price Target$6.00 Potential Upside/Downside+88.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,570,000.00 Net Margins-2,042.01% Pretax Margin-2,040.04% Return on Equity-44.60% Return on Assets-37.58% Debt Debt-to-Equity Ratio0.02 Current Ratio7.19 Quick Ratio7.19 Sales & Book Value Annual Sales$5.72 million Price / Sales87.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book2.34Miscellaneous Outstanding Shares113,080,000Free Float101,990,000Market Cap$503.21 million OptionableOptionable Beta2.20 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Sean McClain (Age 33)Founder, CEO, President & Director Comp: $936.2kDr. Zachariah Jonasson Ph.D. (Age 50)Chief Business Officer & CFO Comp: $98.3kDr. Andreas Busch Ph.D. (Age 61)Chief Innovation Officer & Member of Scientific Advisory Board Comp: $1.56MMr. Todd Bedrick CPASenior VP & Chief Accounting OfficerMr. Alexander Khan CPAVP of Finance & Head of Investor RelationsMs. Karin WierinckChief People OfficerMelissa Patterson Ph.D.Chief of StaffJens Plassmeier Ph.D.Senior VP of Biologics Discovery TechnologyMr. Wen ShaChief of StaffDr. Christine Lemke D.V.M.M.B.A., Ph.D., Senior Vice President of Portfolio & Growth StrategyMore ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPTScan TherapeuticsNASDAQ:TCRXSutro BiopharmaNASDAQ:STROAdaptimmune TherapeuticsNASDAQ:ADAPTenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInsiders & InstitutionsARK Investment Management LLCBought 2,226,794 shares on 7/26/2024Ownership: 4.867%Bank of New York Mellon CorpBought 239,747 shares on 7/26/2024Ownership: 0.253%Institute for Wealth Management LLC.Bought 268,019 shares on 7/25/2024Ownership: 0.452%Sumitomo Mitsui Trust Holdings Inc.Bought 310,946 shares on 7/19/2024Ownership: 0.647%Brookstone Capital ManagementBought 35,691 shares on 7/18/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $4.20 at the beginning of the year. Since then, ABSI stock has increased by 6.7% and is now trading at $4.48. View the best growth stocks for 2024 here. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) issued its earnings results on Monday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.03. The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.50 million. Absci had a negative trailing twelve-month return on equity of 44.60% and a negative net margin of 2,042.01%. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Top institutional shareholders of Absci include ARK Investment Management LLC (4.87%), Sumitomo Mitsui Trust Holdings Inc. (0.65%), Institute for Wealth Management LLC. (0.45%) and Bank of New York Mellon Corp (0.25%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc, Zachariah Jonasson, Karen K Mcginnis, Todd Bedrick, Sean Mcclain and Sarah Korman. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABSI) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
